Background Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy-associated with psoriasis. T helper 17 pathway has been shown to play an important role in PsA.
Objectives In this study, we aimed to investigate concentrations of TH17 pathway cytokines such as IL-17, IL-22 and IL-23 in psoriasis (PsO) with/and without structural bone damage and psoriatic arthritis (PsA), and their relationship with disease activity and clinical findings.
Methods A total number of 74 patients, 24 patients with PsA (mean age 57.5±11.37; 13 women, 11 men) and 25 patients with PsO and structural bone damage (mean age 49±13.92; 11 women, 14 men) and 25 patients with PsO and no structural bone damage (mean age 41±16.77; 7 women, 18 men), were recruited from the Department Internal Medicine 3 of the University of Erlangen-Numberg. Both PsO and PsA patients were evaluated according to the CASPAR criteria. Demographic and disease specific variables were recorded. Bone architecture of the metacarpal heads II and III were assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT, XtremeCT, Scanco, Switzerland). Disease activity was assessed with Disease Activity Score (DAS28). Psoriatic skin and nail disease activity were measured by the PASI.
Results The ages of the patients in the three groups were similar. IL-17A concentrations were significantly differed between the groups (p=0.000). However, for other cytokines there was no difference between PsA and PsO groups. Serum levels of IL-17A were significantly correlated to patient pain of VAS (r=-0.318, p=0.06), VAS patient global assessment (r=0.272, p=0.021), DAS28 (r=-0.394, p=0.001) and PASI (r=0.519, p=0.000) in PsA and PSO. PASI score were also positively correlated with IL23 (r=-0.286, p=0.015) and S100A8 (r=0.298, p=0.011).
Conclusions IL-17A seems to play an important role in development of PsA and bone damage in PsO. This role should be elucidated by further and larger clinical studies.
Disclosure of Interest None declared